Genovate Biotechnology Co Ltd (4130) — Cash Flow Reinvestment Rate
Genovate Biotechnology Co Ltd (4130) has a Cash Flow Reinvestment Rate of 0.63x as of December 2025, reinvesting NT$10.75 Million (capex NT$8.19 Million plus investments NT$-2.56 Million) from operating cash flow of NT$16.93 Million. See free cash flow generation of Genovate Biotechnology Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Genovate Biotechnology Co Ltd Cash Flow Reinvestment Rate (2015–2025)
Historical reinvestment intensity for Genovate Biotechnology Co Ltd across 10 annual periods. For the full cash flow conversion analysis, see 4130 cash generation efficiency.
Annual Cash Flow Reinvestment Rate for Genovate Biotechnology Co Ltd (2015–2025)
Year-by-year capital reinvestment analysis for Genovate Biotechnology Co Ltd. See Genovate Biotechnology Co Ltd (4130) financial flexibility to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.91x | NT$83.63 Million | NT$43.79 Million | NT$61.42 Million | ▲ +21.1% |
| 2024 | 1.58x | NT$86.92 Million | NT$55.11 Million | NT$31.37 Million | ▲ +79.5% |
| 2023 | 0.88x | NT$74.49 Million | NT$84.78 Million | NT$33.34 Million | ▼ -95.5% |
| 2022 | 19.71x | NT$29.76 Million | NT$1.51 Million | NT$24.01 Million | ▲ +4606.1% |
| 2020 | 0.42x | NT$36.47 Million | NT$87.08 Million | NT$27.01 Million | ▼ -69.9% |
| 2019 | 1.39x | NT$61.76 Million | NT$44.43 Million | NT$25.76 Million | ▲ +84.0% |
| 2018 | 0.76x | NT$47.49 Million | NT$62.88 Million | NT$35.26 Million | ▼ -93.9% |
| 2017 | 12.33x | NT$385.65 Million | NT$31.27 Million | NT$38.53 Million | ▲ +1345.3% |
| 2016 | 0.85x | NT$60.22 Million | NT$70.58 Million | NT$40.87 Million | ▼ -91.8% |
| 2015 | 10.42x | NT$338.87 Million | NT$32.53 Million | NT$53.75 Million | — |